Loading
Life sciences · Journal article
Current Urology · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obstructive sleep apnea (OSA) and erectile dysfunction (ED) are highly prevalent disorders that frequently coexist and share overlapping vascular, autonomic, endocrine, inflammatory, metabolic, neurocognitive, and psychological mechanisms. Despite growing recognition of this relationship, OSA remains underrecognized in many urologic settings. This narrative review examines the relationship between OSA and ED, emphasizing shared pathophysiologic mechanisms and their implications for screening and integrated clinical management. A structured search of PubMed and PsycINFO was conducted using terms related to OSA, ED, sleep-disordered breathing, endothelial dysfunction, intermittent hypoxia, rapid eye movement sleep, continuous positive airway pressure, testosterone, and sexual dysfunction. Priority was given to systematic reviews, meta-analyses, randomized trials, and clinically relevant observational studies published through early 2025. Current evidence indicates that OSA contributes to ED through multiple interacting mechanisms, including endothelial dysfunction, impaired nitric oxide signaling, chronic intermittent hypoxia, sympathetic nervous system hyperactivation, inflammation, metabolic dysregulation, hormonal alterations, disrupted sleep architecture, and psychological distress. Men presenting with ED frequently demonstrate an increased risk of undiagnosed OSA, particularly in the presence of obesity, hypertension, diabetes mellitus, excessive daytime sleepiness, loud snoring, or treatment-resistant sexual dysfunction. Continuous positive airway pressure therapy, weight reduction, and comprehensive cardiometabolic management may improve erectile function in selected patients, although treatment response varies. Recognition of ED as a potential clinical marker of OSA provides an opportunity for earlier diagnosis, multidisciplinary intervention, and improved sexual, cardiovascular, metabolic, and quality-of-life outcomes.